Runs comprehensive molecular tumor profiling (DNA/RNA sequencing) to help oncologists match cancer patients to targeted therapies.
Runs comprehensive molecular tumor profiling (DNA/RNA sequencing) to help oncologists match cancer patients to targeted therapies.
Paid per test: Medicare and private insurers reimburse the lab for each tumor-sequencing report, while drug makers pay for access to its anonymised molecular and outcomes data and for companion-diagnostic development. Volumes depend on oncologists ordering the test and insurers agreeing to pay.
Moat: narrow (data, process know-how, scale). A large proprietary tumor molecular/clinical-outcomes database supports AI-driven biomarker discovery that is hard to replicate quickly.
Headquarters: Irving, Texas, US · Founded: 2008 · Employees: 1,846
Size Caris Life Sciences (CAI) is a United States Health Care company (Biotechnology) with a market value of $5.59B, the 1101st largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.50 on 18 Nov 2026.
Performance Over six months the shares gained 24.2%, against -1.4% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 61.5% over the last twelve months (peer median +3.6%); the operating margin is 13.3% (peer median -18.9%).
Valuation It trades at 79.4× forward earnings against a peer median of 47.3× (2nd most expensive of 7).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +61%, so the hurdle is -43 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 24.6 points above its cost of capital (8.4% WACC).
Short interest Short interest is 4.0% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $1.05B | $812M | $412M | $306M |
| Revenue growth | — | +97% | +35% | — |
| Gross profit | $724M | $539M | $179M | $89.3M |
| EBITDA | $162M | $67.7M | -$208M | -$271M |
| Net income | $96.1M | -$68.1M | -$282M | -$341M |
| Free cash flow | $21.2M | $59.2M | -$254M | -$298M |
| Capital expenditure | $55.0M | $16.3M | $8.44M | $22.3M |
| Total debt | $463M | $428M | $424M | $217M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Caris Life Sciences CAI | $5.59B | +24% | +61% | 13% | 79.4× | 18.2% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
| Guardant Health GH | $19.6B | +26% | +42% | -39% | n/a | n/a |
| Tempus AI TEM | $11.6B | +39% | +37% | -18% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CAI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -37.3% | +1.0% | lowest of 21 |
| 6-month return | +24.2% | -1.4% | 7th highest of 21 |
| Distance from 52-week high | -46.6% | -31.9% | 6th lowest of 21 |
| Revenue growth (TTM) | +61.5% | +3.6% | 3rd highest of 15 |
| Operating margin | 13.3% | -18.9% | 4th highest of 16 |
| Forward P/E | 79.4× | 47.3× | 2nd most expensive of 7 |
| Growth the price implies (Req g, 7 yrs) | 18.2% | 32.4% | 2nd least demanding of 6 |
| Growth delivered (Del g) | +61.5% | +16.4% | highest of 6 |
| Hurdle (Req g minus delivered) | -43.3 pp | +10.7 pp | least demanding of 6 |
| ROIC minus cost of capital | +24.6 pp | -14.7 pp | 2nd highest of 13 |
| EV / EBITDA | 32.6× | n/a | — |
| Net debt / EBITDA | -1.9× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 79.4× | 18.2% | +61.5% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 64.3× | 36.9% | +26.2% |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | n/a | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | n/a | -6.5% | -10.0% |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | n/a | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 97.0× | 25.9% | +16.4% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | n/a | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 12.8× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 30.3× | 32.4% | +7.1% |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 77.1× | n/a | n/a |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 12.0× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | n/a | 47.2% | +16.6% |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | n/a | n/a | n/a |